1. Xavier, R.J.; Podolsky, D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448, 427–434. [CrossRef]
2. Abraham, C.; Cho, J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009, 361, 2066–2078. [CrossRef] [PubMed]
3. Danese, S.; Fiocchi, C. Ulcerative colitis. N. Engl. J. Med. 2011, 365, 1713–1725. [CrossRef] [PubMed]
4. Shalapour, S.; Karin, M. Immunity, inflammation, and cancer: An eternal fight between good and evil. J. Clin. Investig. 2015, 125, 3347–3355. [CrossRef]
5. van Hogezand, R.A.; Eichhorn, R.F.; Choudry, A.; Veenendaal, R.A.; Lamers, C.B. Malignancies in inflammatory bowel disease: Fact or fiction? Scand J. Gastroenterol. Suppl. 2002, 48–53. [CrossRef] [PubMed]
6. Terzic´, J.; Grivennikov, S.; Karin, E.; Karin, M. Inflammation and colon cancer. Gastroenterology 2010, 138, 2101–2114.e2105. [CrossRef]
7. Asl, M.N.; Hosseinzadeh, H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. PhytoTher. Res.
2008, 22, 709–724. [CrossRef]
8. Li, J.Y.; Cao, H.Y.; Liu, P.; Cheng, G.H.; Sun, M.Y. Glycyrrhizic acid in the treatment of liver diseases: Literature review. BioMed. Res. Int. 2014, 2014, 872139. [CrossRef]
9. Wang, C.; Chen, L.; Xu, C.; Shi, J.; Chen, S.; Tan, M.; Chen, J.; Zou, L.; Chen, C.; Liu, Z.; et al. A Comprehensive Review for Phytochemical, Pharmacological, and Biosynthesis Studies on Glycyrrhiza spp. Am. J. Chin. Med. 2020, 48, 17–45. [CrossRef]
10. Wu, S.Y.; Wang, W.J.; Dou, J.H.; Gong, L.K. Research progress on the protective effects of licorice-derived 18β-glycyrrhetinic acid against liver injury. Acta Pharmacol. Sin. 2021, 42, 18–26. [CrossRef]
11. Shi, X.; Yu, L.; Zhang, Y.; Liu, Z.; Zhang, H.; Zhang, Y.; Liu, P.; Du, P. Glycyrrhetinic acid alleviates hepatic inflammation injury in viral hepatitis disease via a HMGB1-TLR4 signaling pathway. Int. Immunopharmacol. 2020, 84, 106578. [CrossRef]
12. Yang, R.; Yuan, B.C.; Ma, Y.S.; Zhou, S.; Liu, Y. The anti-inflammatory activity of licorice, a widely used Chinese herb. Pharm. Biol.
2017, 55, 5–18. [CrossRef]
13. Pastorino, G.; Cornara, L.; Soares, S.; Rodrigues, F.; Oliveira, M. Liquorice (Glycyrrhiza glabra): A phytochemical and pharmaco- logical review. PhytoTher. Res. 2018, 32, 2323–2339. [CrossRef]
14. Dastagir, G.; Rizvi, M.A. Review-Glycyrrhiza glabra L. (Liquorice). Pak J. Pharm. Sci. 2016, 29, 1727–1733.
15. Smolarczyk, R.; Cichon´, T.; Matuszczak, S.; Mitrus, I.; Lesiak, M.; Kobusin´ska, M.; Kamysz, W.; Jarosz, M.; Sieron´, A.; Szala, S. The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Arch. Immunol. Ther. Exp. 2012, 60, 391–399. [CrossRef]
16. Kang, R.; Zhang, Q.; Zeh, H.J., 3rd; Lotze, M.T.; Tang, D. HMGB1 in cancer: Good, bad, or both? Clin. Cancer Res. 2013, 19, 4046–4057. [CrossRef] [PubMed]
17. Tang, D.; Kang, R.; Zeh, H.J., 3rd; Lotze, M.T. High-mobility group box 1 and cancer. Biochim. Biophys. Acta 2010, 1799, 131–140. [CrossRef]
18. Yu, M.; Wang, H.; Ding, A.; Golenbock, D.T.; Latz, E.; Czura, C.J.; Fenton, M.J.; Tracey, K.J.; Yang, H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26, 174–179. [CrossRef]
19. Srikrishna, G.; Freeze, H.H. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009, 11, 615–628. [CrossRef] [PubMed]
20. Vergoten, G.; Bailly, C. N-glycosylation of High Mobility Group Box 1 protein (HMGB1) modulates the interaction with glycyrrhizin: A molecular modeling study. Comput. Biol. Chem. 2020, 88, 107312. [CrossRef] [PubMed]
21. Su, X.; Wu, L.; Hu, M.; Dong, W.; Xu, M.; Zhang, P. Glycyrrhizic acid: A promising carrier material for anticancer therapy. Biomed. Pharmacother. 2017, 95, 670–678. [CrossRef]
22. Dong, Y.D.; Cui, L.; Peng, C.H.; Cheng, D.F.; Han, B.S.; Huang, F. Expression and clinical significance of HMGB1 in human liver cancer: Knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol. Rep. 2013, 29, 87–94. [CrossRef]
23. Tripathi, A.; Shrinet, K.; Kumar, A. HMGB1 protein as a novel target for cancer. Toxicol. Rep. 2019, 6, 253–261. [CrossRef]
24. Liu, L.; Jiang, Y.; Steinle, J.J. Epac1 and Glycyrrhizin Both Inhibit HMGB1 Levels to Reduce Diabetes-Induced Neuronal and Vascular Damage in the Mouse Retina. J. Clin. Med. 2019, 8, 772. [CrossRef] [PubMed]
25. Zhang, H.; Zhang, R.; Chen, J.; Shi, M.; Li, W.; Zhang, X. High Mobility Group Box1 Inhibitor Glycyrrhizic Acid Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats. Kidney Blood Press Res. 2017, 42, 894–904. [CrossRef]
26. Ekanayaka, S.A.; McClellan, S.A.; Barrett, R.P.; Kharotia, S.; Hazlett, L.D. Glycyrrhizin Reduces HMGB1 and Bacterial Load in Pseudomonas aeruginosa Keratitis. Investig. Ophthalmol. Vis. Sci. 2016, 57, 5799–5809. [CrossRef] [PubMed]
27. Liu, X.; Zhuang, J.; Wang, D.; Lv, L.; Zhu, F.; Yao, A.; Xu, T. Glycyrrhizin suppresses inflammation and cell apoptosis by inhibition of HMGB1 via p38/p-JUK signaling pathway in attenuating intervertebral disc degeneration. Am. J. Transl. Res. 2019, 11, 5105–5113. [PubMed]
28. Wu, X.; Wang, W.; Chen, Y.; Liu, X.; Wang, J.; Qin, X.; Yuan, D.; Yu, T.; Chen, G.; Mi, Y.; et al. Glycyrrhizin Suppresses the Growth of Human NSCLC Cell Line HCC827 by Downregulating HMGB1 Level. BioMed. Res. Int. 2018, 2018, 6916797. [CrossRef] [PubMed]
29. Huan, C.C.; Wang, H.X.; Sheng, X.X.; Wang, R.; Wang, X.; Mao, X. Glycyrrhizin inhibits porcine epidemic diarrhea virus infection and attenuates the proinflammatory responses by inhibition of high mobility group box-1 protein. Arch. Virol. 2017, 162, 1467–1476. [CrossRef] [PubMed]
30. Chen, X.; Fang, D.; Li, L.; Chen, L.; Li, Q.; Gong, F.; Fang, M. Glycyrrhizin ameliorates experimental colitis through attenuating interleukin-17-producing T cell responses via regulating antigen-presenting cells. Immunol. Res. 2017, 65, 666–680. [CrossRef]
31. Zhang, X.M.; Hu, X.; Ou, J.Y.; Chen, S.S.; Nie, L.H.; Gao, L.; Zhu, L.L. Glycyrrhizin Ameliorates Radiation Enteritis in Mice Accompanied by the Regulation of the HMGB1/TLR4 Pathway. Evid. Based Complement. Alternat. Med. 2020, 2020, 8653783. [CrossRef]
32. Khan, R.; Khan, A.Q.; Lateef, A.; Rehman, M.U.; Tahir, M.; Ali, F.; Hamiza, O.O.; Sultana, S. Glycyrrhizic acid suppresses the development of precancerous lesions via regulating the hyperproliferation, inflammation, angiogenesis and apoptosis in the colon of Wistar rats. PLoS ONE 2013, 8, e56020. [CrossRef] [PubMed]
33. Tanaka, T.; Kohno, H.; Suzuki, R.; Yamada, Y.; Sugie, S.; Mori, H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003, 94, 965–973. [CrossRef] [PubMed]
34. De Robertis, M.; Massi, E.; Poeta, M.L.; Carotti, S.; Morini, S.; Cecchetelli, L.; Signori, E.; Fazio, V.M. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J. Carcinog. 2011, 10, 9. [CrossRef]
35. Mollica, L.; De Marchis, F.; Spitaleri, A.; Dallacosta, C.; Pennacchini, D.; Zamai, M.; Agresti, A.; Trisciuoglio, L.; Musco, G.; Bianchi, M.E. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol. 2007, 14, 431–441. [CrossRef]
36. Vergoten, G.; Bailly, C. Analysis of glycyrrhizin binding to protein HMGB1. Med. Drug Discov. 2020, 7, 100058. [CrossRef]
37. Chen, J.; Liu, X.; Zhang, J.; Zhao, Y. Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J. Cell Physiol. 2012, 227, 3629–3638. [CrossRef] [PubMed]
38. Kawanishi, S.; Ohnishi, S.; Ma, N.; Hiraku, Y.; Murata, M. Crosstalk between DNA Damage and Inflammation in the Multiple Steps of Carcinogenesis. Int. J. Mol. Sci. 2017, 18, 1808. [CrossRef]
39. Scaffidi, P.; Misteli, T.; Bianchi, M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002,
418, 191–195. [CrossRef]
40. Ahmed, S.; Kobayashi, H.; Afroz, T.; Ma, N.; Oikawa, S.; Kawanishi, S.; Murata, M.; Hiraku, Y. Nitrative DNA damage in lung epithelial cells exposed to indium nanoparticles and indium ions. Sci. Rep. 2020, 10, 10741. [CrossRef] [PubMed]
41. Mukherjee, S.; Mukherjee, S.; Bhattacharya, S.; Sinha Babu, S.P. Surface proteins of Setaria cervi induce inflammation in macrophage through Toll-like receptor 4 (TLR4)-mediated signalling pathway. Parasite Immunol. 2017, 39. [CrossRef] [PubMed]
42. Yang, H.; Tracey, K.J. Targeting HMGB1 in inflammation. Biochim. Biophys. Acta 2010, 1799, 149–156. [CrossRef] [PubMed]
43. Zhu, L.; Li, X.; Chen, Y.; Fang, J.; Ge, Z. High-mobility group box 1: A novel inducer of the epithelial-mesenchymal transition in colorectal carcinoma. Cancer Lett. 2015, 357, 527–534. [CrossRef]
44. Shang, J.; Liu, W.; Yin, C.; Chu, H.; Zhang, M. Cucurbitacin E ameliorates lipopolysaccharide-evoked injury, inflammation and MUC5AC expression in bronchial epithelial cells by restraining the HMGB1-TLR4-NF-κB signaling. Mol. Immunol. 2019, 114, 571–577. [CrossRef]
45. Murata, M.; Thanan, R.; Ma, N.; Kawanishi, S. Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis.
J. BioMed. Biotechnol. 2012, 2012, 623019. [CrossRef] [PubMed]
46. Ma, N.; Kawanishi, M.; Hiraku, Y.; Murata, M.; Huang, G.W.; Huang, Y.; Luo, D.Z.; Mo, W.G.; Fukui, Y.; Kawanishi, S. Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: The relation to STAT3 activation and EGFR expression. Int. J. Cancer 2008, 122, 2517–2525. [CrossRef] [PubMed]
47. Landskron, G.; De la Fuente, M.; Thuwajit, P.; Thuwajit, C.; Hermoso, M.A. Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014, 2014, 149185. [CrossRef] [PubMed]
48. Ayob, A.Z.; Ramasamy, T.S. Cancer stem cells as key drivers of tumour progression. J. BioMed. Sci. 2018, 25, 20. [CrossRef] [PubMed]
49. Schewe, M.; Franken, P.F.; Sacchetti, A.; Schmitt, M.; Joosten, R.; Böttcher, R.; van Royen, M.E.; Jeammet, L.; Payré, C.; Scott, P.M.; et al. Secreted Phospholipases A2 Are Intestinal Stem Cell Niche Factors with Distinct Roles in Homeostasis, Inflammation, and Cancer. Cell Stem Cell 2016, 19, 38–51. [CrossRef]
50. Kawanishi, S.; Ohnishi, S.; Ma, N.; Hiraku, Y.; Oikawa, S.; Murata, M. Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells. Genes Environ. 2016, 38, 26. [CrossRef]
51. Ding, X.; Hiraku, Y.; Ma, N.; Kato, T.; Saito, K.; Nagahama, M.; Semba, R.; Kuribayashi, K.; Kawanishi, S. Inducible nitric oxide synthase-dependent DNA damage in mouse model of inflammatory bowel disease. Cancer Sci. 2005, 96, 157–163. [CrossRef]
52. Munro, M.J.; Wickremesekera, S.K.; Peng, L.; Tan, S.T.; Itinteang, T. Cancer stem cells in colorectal cancer: A review. J. Clin. Pathol.
2018, 71, 110–116. [CrossRef]
53. Saygin, C.; Matei, D.; Majeti, R.; Reizes, O.; Lathia, J.D. Targeting Cancer Stemness in the Clinic: From Hype to Hope. Cell Stem Cell 2019, 24, 25–40. [CrossRef] [PubMed]
54. Wang, S.; Ma, N.; Zhao, W.; Midorikawa, K.; Kawanishi, S.; Hiraku, Y.; Oikawa, S.; Zhang, Z.; Huang, G.; Murata, M. Inflammation- Related DNA Damage and Cancer Stem Cell Markers in Nasopharyngeal Carcinoma. Mediat. Inflamm. 2016, 2016, 9343460. [CrossRef]
55. Braitsch, C.M.; Azizoglu, D.B.; Htike, Y.; Barlow, H.R.; Schnell, U.; Chaney, C.P.; Carroll, T.J.; Stanger, B.Z.; Cleaver, O. LATS1/2 suppress NFκB and aberrant EMT initiation to permit pancreatic progenitor differentiation. PLoS Biol. 2019, 17, e3000382. [CrossRef]
56. Rivera-Reyes, A.; Ye, S.; Gloria, E.M.; Egolf, S.; Gabrielle, E.C.; Chor, S.; Liu, Y.; Posimo, J.M.; Park, P.M.C.; Pak, K.; et al. YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. Cell Death Dis. 2018, 9, 1108. [CrossRef]
57. Qian, F.; Xiao, J.; Gai, L.; Zhu, J. HMGB1-RAGE signaling facilitates Ras-dependent Yap1 expression to drive colorectal cancer stemness and development. Mol. Carcinog. 2019, 58, 500–510. [CrossRef] [PubMed]
58. Fan, H.; Jiang, C.; Zhong, B.; Sheng, J.; Chen, T.; Chen, Q.; Li, J.; Zhao, H. Matrine Ameliorates Colorectal Cancer in Rats via Inhibition of HMGB1 Signaling and Downregulation of IL-6, TNF-α, and HMGB1. J. Immunol. Res. 2018, 2018, 5408324. [CrossRef]
59. Grivennikov, S.; Karin, E.; Terzic, J.; Mucida, D.; Yu, G.Y.; Vallabhapurapu, S.; Scheller, J.; Rose-John, S.; Cheroutre, H.; Eckmann, L.; et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15, 103–113. [CrossRef] [PubMed]
60. Cai, J.; Zhang, N.; Zheng, Y.; de Wilde, R.F.; Maitra, A.; Pan, D. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 2010, 24, 2383–2388. [CrossRef]
61. Karin, M.; Clevers, H. Reparative inflammation takes charge of tissue regeneration. Nature 2016, 529, 307–315. [CrossRef] [PubMed]
62. Huang, Y.J.; Yang, C.K.; Wei, P.L.; Huynh, T.T.; Whang-Peng, J.; Meng, T.C.; Hsiao, M.; Tzeng, Y.M.; Wu, A.T.; Yen, Y. Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways. J. Hematol. Oncol. 2017, 10, 60. [CrossRef]
63. Moya, I.M.; Halder, G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat. Rev. Mol. Cell Biol.
2019, 20, 211–226. [CrossRef]
64. Taniguchi, K.; Moroishi, T.; de Jong, P.R.; Krawczyk, M.; Grebbin, B.M.; Luo, H.; Xu, R.H.; Golob-Schwarzl, N.; Schweiger, C.; Wang, K.; et al. YAP-IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. Proc. Natl. Acad. Sci. USA 2017, 114, 1643–1648. [CrossRef]
65. Taniguchi, K.; Wu, L.W.; Grivennikov, S.I.; de Jong, P.R.; Lian, I.; Yu, F.X.; Wang, K.; Ho, S.B.; Boland, B.S.; Chang, J.T.; et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 2015, 519, 57–62. [CrossRef]
66. Bromberg, J.; Wang, T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009, 15, 79–80. [CrossRef] [PubMed]
67. De Simone, V.; Franzè, E.; Ronchetti, G.; Colantoni, A.; Fantini, M.C.; Di Fusco, D.; Sica, G.S.; Sileri, P.; MacDonald, T.T.; Pallone, F.; et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene 2015, 34, 3493–3503. [CrossRef]
68. Shibata, M.; Hoque, M.O. Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer. Cancers 2019, 11, 732. [CrossRef] [PubMed]
69. Chung, S.S.; Vadgama, J.V. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling. Anticancer Res. 2015, 35, 39–46.
70. Grivennikov, S.I.; Karin, M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21, 11–19. [CrossRef] [PubMed]
71. Kim, T.; Lim, D.S. The SRF-YAP-IL6 axis promotes breast cancer stemness. Cell Cycle 2016, 15, 1311–1312. [CrossRef]
72. Zhang, L.; Shi, H.; Chen, H.; Gong, A.; Liu, Y.; Song, L.; Xu, X.; You, T.; Fan, X.; Wang, D.; et al. Dedifferentiation process driven by radiotherapy-induced HMGB1/TLR2/YAP/HIF-1α signaling enhances pancreatic cancer stemness. Cell Death Dis. 2019, 10, 724. [CrossRef]
73. Piccolo, S.; Dupont, S.; Cordenonsi, M. The biology of YAP/TAZ: Hippo signaling and beyond. Physiol. Rev. 2014, 94, 1287–1312. [CrossRef]
74. Panciera, T.; Azzolin, L.; Fujimura, A.; Di Biagio, D.; Frasson, C.; Bresolin, S.; Soligo, S.; Basso, G.; Bicciato, S.; Rosato, A.; et al. Induction of Expandable Tissue-Specific Stem/Progenitor Cells through Transient Expression of YAP/TAZ. Cell Stem Cell 2016, 19, 725–737. [CrossRef] [PubMed]
75. Yu, F.X.; Guan, K.L. The Hippo pathway: Regulators and regulations. Genes Dev. 2013, 27, 355–371. [CrossRef]
76. Camargo, F.D.; Gokhale, S.; Johnnidis, J.B.; Fu, D.; Bell, G.W.; Jaenisch, R.; Brummelkamp, T.R. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 2007, 17, 2054–2060. [CrossRef] [PubMed]
77. Wang, L.; Zhang, Z.; Yu, X.; Huang, X.; Liu, Z.; Chai, Y.; Yang, L.; Wang, Q.; Li, M.; Zhao, J.; et al. Unbalanced YAP-SOX9 circuit drives stemness and malignant progression in esophageal squamous cell carcinoma. Oncogene 2019, 38, 2042–2055. [CrossRef]
78. Zhou, H.; Li, G.; Huang, S.; Feng, Y.; Zhou, A. SOX9 promotes epithelial-mesenchymal transition via the Hippo-YAP signaling pathway in gastric carcinoma cells. Oncol. Lett. 2019, 18, 599–608. [CrossRef]
79. Aguilar-Medina, M.; Avendaño-Félix, M.; Lizárraga-Verdugo, E.; Bermúdez, M.; Romero-Quintana, J.G.; Ramos-Payan, R.; Ruíz-García, E.; López-Camarillo, C. SOX9 Stem-Cell Factor: Clinical and Functional Relevance in Cancer. J. Oncol. 2019, 2019, 6754040. [CrossRef]
80. Hiramoto, K.; Yokoyama, S.; Yamate, Y. Ultraviolet A eye irradiation ameliorates colon carcinoma induced by azoxymethane and dextran sodium sulfate through β-endorphin and methionine-enkephalin. Photodermatol. PhotoImmunol. PhotoMed. 2017, 33, 84–91. [CrossRef]
81. Yokoyama, S.; Hiramoto, K.; Koyama, M.; Ooi, K. Impaired skin barrier function in mice with colon carcinoma induced by azoxymethane and dextran sodium sulfate. Biol. Pharm. Bull 2015, 38, 947–950. [CrossRef] [PubMed]
論文の公開元へ
